由 浙江金投盛源股权投资有限公司 撰写的 《合成生物行业&投引策略研究报告》 已发布 ，该报告从技术路径、市场格局、代表企业、产业集群、政策 动向等多维度分析解析，为业内人士提供系统性的行业洞察与投资参考。 完整版 研究报告获取方式： 扫码， 添加小编微信 获取【完整版】 加好友，务必备注： 姓名+公司+职务 研究报告部分内容节选： 浙江会设盛调股权投资有限公 金投盛源成立于2023年6月,注册资本2000万元,是浙江省创新投资集团旗下的市场化股权投资平台 主导、联合金浦产业投资基金管理有限公司、苏州工业园区元天原点创业投资管理有限公司、中保投资有 限责任公司、嘉兴浙华嘉融投资管理有限公司等国内知名投资机构，共同出资组建的市场化、专业化股权 投资平台。 公司致力于服务浙江省级政府产业基金运作提质增效,全力助推浙江省打造现代化产业体系,借鉴股 东方的优秀理念和机制、整合贯通各合作方的产业和资本资源,通过守正创新、快速迭代,持续打造具有 金投盛源自身特色的投资运作管理体系。公司主要围绕新材料、新技术、生物医药等领域开展股权投资, 已投资基金的基金总规模合计超100亿元，并将在基金设立组建、重大项目投资、优质项目招 ...

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由仅作新材料相关领域介绍，本文不构成任何投资建议！转载请注明来源！ 请添加下方微信 添加微信请备注： 姓名+公司+职务 中国石油天然气股份有限公司炼化新材料公司副总经理、生物制造和精细化工事业部总经理 李阳 ，蓝海新材料公司党委委员、副总经理 劳国瑞 等一行 到访天津大学卫津路校区，与中国科学院院士、合成生物技术全国重点实验室主任、天津大学合成生物与生物制造学院院长 元英进 及学院科研团队举行 专题座谈，就合成生物与生物制造领域合作展开深度对接，展现双方高效务实的工作作风。 双方围绕 合成生物与生物制造领域 展开了一整天的深度对接。 学院专家、教授系统讲授了多个前沿技术项目，与中石油团队进行了详细剖析与充分研 讨。从基础研究到产业应用，从技术路线到合作模式，双方坦诚交流、精准对接，展现了高标准谋划、高效率推进、高质量落实的坚定决心。 从2月4日集团层面战略签约，到2月10日业务层面深度对接， 短短6天时间，双方合作即实现从顶层设计到具体落实的快速推进 ，充分体现了天津大学与 中国石油携手打造世界一流大学与世界一流企业的坚定决心与高效执行力 ...

在全球推进绿色转型与"双碳"目标的战略背景下，生物基化学品与材料作为生物制造产业的核心支 柱，凭借原料可再生、全生命周期低碳环保等核心优势，正加速替代传统石油基产品，在包装、纺 织、汽车等领域展现出广阔应用前景，成为全球产业绿色转型的关键赛道。 我国高度重视该领域发展，将生物基新材料列为关键战略材料，多项产业扶持政策持续落地。然 而，产业仍面临包括综合成本竞争力、原料供应链稳定、产品性能优化及终端市场接受度等关键问 题。 基于此， 2026年3月31日-4月1日 ，"第五届中国合成生物学及生物制造大会"将在杭州举办，其中设 置 【 生物基化学品与材料专场】 ，旨在汇聚产学研用多方智慧，破解产业发展难题，助力生物基 化学品与材料产业高质量发展。 大会介绍 0 1 大会时间 | 2026年3月31日-4月1日 大会地点 | 杭州市 大会规模 | 1000人 主办单位 | synbio深波 承办单位 | 享融智云 媒体支持 | synbio新农食、synbio新美护、synbio新材料、生物制造圈、合成生物学俱乐部 扫码 免费 报名参会 ↓↓↓ 论坛设置 0 2 拟定话题 0 3 *以大会现场实际议程为准 商务合作 ...

大会介绍 0 1 大会时间 | 2026年3月31日-4月1日 大会地点 | 杭州市 大会规模 | 1000人 主办单位 | synbio深波 在全球推进绿色转型与"双碳"目标的战略背景下，生物基化学品与材料作为生物制造产业的核心支 柱，凭借原料可再生、全生命周期低碳环保等核心优势，正加速替代传统石油基产品，在包装、纺 织、汽车等领域展现出广阔应用前景，成为全球产业绿色转型的关键赛道。 我国高度重视该领域发展，将生物基新材料列为关键战略材料，多项产业扶持政策持续落地。然 而，产业仍面临包括综合成本竞争力、原料供应链稳定、产品性能优化及终端市场接受度等关键问 题。 基于此， 2026年3月31日-4月1日 ，"第五届中国合成生物学及生物制造大会"将在杭州举办，其中设 置 【 生物基化学品与材料专场】 ，旨在汇聚产学研用多方智慧，破解产业发展难题，助力生物基 化学品与材料产业高质量发展。 承办单位 | 享融智云 商务合作 0 4 媒体支持 | synbio新农食、synbio新美护、synbio新材料、生物制造圈、合成生物学俱乐部 扫码 免费 报名参会 论坛设置 0 2 | | 会场一 | 会场二 | 会场三 | ...

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field that disrupts traditional production methods, presenting it as a new growth point for optimizing industrial structure and transforming economic models [1]. Group 1: Current Status and Trends - The "2025 China Synthetic Biomanufacturing Industry Development White Paper" was officially released on August 1, highlighting the current state and trends of biomanufacturing [1]. - The report analyzes the global biomanufacturing industry, including key platform facilities and a comparative study of the US and China in this sector [7]. Group 2: Policy Landscape - The white paper outlines major domestic and international policies affecting biomanufacturing from 2024 to 2025, providing insights into regulatory frameworks [7]. Group 3: Industry Map and Applications - It presents a comprehensive map of the Chinese biomanufacturing industry and identifies key application areas, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [7]. Group 4: Key Enterprises - The report selects ten leading enterprises in the Chinese biomanufacturing sector and details the strategic directions of 15 listed companies in synthetic biology [7][8]. Group 5: Investment and Challenges - The document discusses the investment landscape in synthetic biology from 2024 to mid-2025 and addresses the challenges faced by the biomanufacturing industry in China, along with proposed countermeasures [7].

Core Viewpoint - The article discusses the development of next-generation biomanufacturing technologies based on extreme microorganisms, particularly Halomonas bluephagenes, emphasizing their potential to achieve sustainable industrial production while addressing the challenges of traditional microbial platforms [2][3]. Group 1: Need for Biomanufacturing Transition - The biomanufacturing technology using microorganisms is increasingly recognized as an environmentally friendly alternative for producing diverse chemicals, driven by advancements in synthetic biology [8]. - Current industrial biotechnology faces limitations due to high energy-consuming sterilization processes and inefficiencies in continuous production, necessitating the shift to next-generation biomanufacturing (NGIB) using extreme microorganisms [9][10]. Group 2: Industrial Value of Extreme Microorganisms - Extreme microorganisms, such as thermophiles, acidophiles, and halophiles, exhibit remarkable growth capabilities in harsh environments, making them suitable for industrial applications [11]. - These microorganisms can significantly reduce sterilization needs and enhance production efficiency, positioning them as valuable assets in sustainable biomanufacturing [14][15]. Group 3: Development of Next-Generation Industrial Biotechnology - Halomonas bluephagenes, a halophilic bacterium, shows promise in producing biopolymers like PHB, with advantages in genetic engineering and metabolic pathway optimization [13][16]. - The development of genetic tools and adaptive evolution strategies has led to significant improvements in product yields and metabolic efficiency [17][20]. Group 4: Metabolic Engineering and Product Synthesis - Metabolic engineering is crucial for enhancing the production of target metabolites in extreme microorganisms, with strategies focusing on cell morphology optimization and dynamic control of protein degradation rates [20][21]. - Halomonas bluephagenes has been engineered to utilize various low-cost substrates, including starch and food waste, for the production of biopolymers and high-value chemicals [27][33]. Group 5: Industrial Applications and Future Directions - The NGIB technology has been successfully applied in the production of biodegradable materials like PHA and various fine chemicals, with industrial-scale implementations already underway [39]. - Future advancements will require integrating cutting-edge technologies and optimizing metabolic pathways to enhance the efficiency and sustainability of biomanufacturing processes [41][43].

在全球推进绿色转型与"双碳"目标的战略背景下，生物基化学品与材料作为生物制造产业的核心支 柱，凭借原料可再生、全生命周期低碳环保等核心优势，正加速替代传统石油基产品，在包装、纺 织、汽车等领域展现出广阔应用前景，成为全球产业绿色转型的关键赛道。 我国高度重视该领域发展，将生物基新材料列为关键战略材料，多项产业扶持政策持续落地。然 而，产业仍面临包括综合成本竞争力、原料供应链稳定、产品性能优化及终端市场接受度等关键问 题。 基于此， 2026年3月31日-4月1日 ，"第五届中国合成生物学及生物制造大会"将在杭州举办，其中设 置 【 生物基化学品与材料专场】 ，旨在汇聚产学研用多方智慧，破解产业发展难题，助力生物基 化学品与材料产业高质量发展。 大会介绍 0 1 大会时间 | 2026年3月31日-4月1日 大会地点 | 杭州市 大会规模 | 1000人 主办单位 | synbio深波 承办单位 | 享融智云 媒体支持 | synbio新农食、synbio新美护、synbio新材料、生物制造圈、合成生物学俱乐部 扫码 免费 报名参会 论坛设置 0 2 | | 会场一 | 会场二 | 会场三 | | --- | ...

Core Insights - The report titled "Synthetic Biology Industry & Investment Strategy Research Report" provides a comprehensive analysis of the synthetic biology sector, covering technical pathways, market landscape, representative companies, industrial clusters, and policy trends [2]. Group 1: Company Overview - Zhejiang Jintou Shengyuan Equity Investment Co., Ltd. was established in June 2023 with a registered capital of 200 million yuan, serving as a market-oriented equity investment platform under the Zhejiang Provincial Innovation Investment Group [6]. - The company focuses on sectors such as new materials, new technologies, and biomedicine, with a total fund scale exceeding 10 billion yuan, aiming to enhance the operation of provincial government industrial funds [6][34]. Group 2: Market Dynamics - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%. It is projected to reach nearly $50 billion by 2028 [25]. - The Chinese market is expected to be approximately 10 billion yuan in 2024, continuing to grow to 12.406 billion yuan in 2025 [25]. Group 3: Technological Advancements - Shanghai Kasei Biotechnology Co., Ltd. has pioneered the large-scale production technology of long-chain dicarboxylic acids through biological methods, breaking the monopoly of chemical synthesis [7]. - Ginkgo Bioworks has expanded its offerings into life science tools and services, integrating various foundational tools to assist downstream clients in producing desired biological products [14][15]. Group 4: Investment Strategies - The report emphasizes the importance of strategic partnerships and collaborations in the synthetic biology sector, highlighting the need for investment in innovative technologies and platforms to drive growth [19][25]. - The investment landscape is characterized by a shift from pure service models to integrated solutions that combine research and product offerings, particularly in the context of AI and automation [15][16].

Core Viewpoint - Biomanufacturing is a crucial technology path for achieving green, low-carbon, and sustainable development, evolving rapidly across the entire industry chain from raw materials to products [3][4]. Group 1: Key Technological Development Trends in Biomanufacturing - Biomanufacturing is transitioning from traditional fermentation-driven methods to intelligent and bio-design-driven manufacturing paradigms [4]. - The raw material system in biomanufacturing is diversifying from grain dependence to non-grain biomass, alleviating competition for land and resources [8]. - High-performance strains and enzymes are evolving towards precision and intelligence, with advancements in gene editing technologies like CRISPR facilitating rapid development [9][10]. Group 2: Challenges in China's Biomanufacturing - China's biomanufacturing heavily relies on starch-based food resources, with about 90% of primary raw materials sourced from crops like corn, leading to resource conflicts [17]. - There is a significant shortfall in the autonomous control of microbial strains, with a high dependency on foreign resources for key industrial strains and enzyme preparations [18]. - The design of biocatalysts and underlying technologies in China is lagging, relying on foreign-developed algorithms and platforms for enzyme design [20]. Group 3: Future Key Technological Development Directions - Focus on developing efficient conversion technologies for one-carbon raw materials and utilizing non-grain biomass resources [26]. - Emphasize intelligent design and creation of industrial enzymes and strains, leveraging AI and big data for precise discovery and development [28]. - Establish smart cell factories and precise bioprocessing technologies, integrating real-time monitoring and AI-driven decision-making [30]. Group 4: Product System Expansion Driven by Biomanufacturing - Biomanufacturing is expected to drive the development of high-energy-density biofuels, sustainable materials, and innovative food products, contributing to economic benefits and social value [32]. - In the energy sector, focus on renewable alternatives like bio-aviation fuel and bio-hydrogen [33]. - In the chemical sector, breakthroughs in bio-based platform compounds are essential for supporting decarbonization efforts in the chemical industry [33].

生物制造政策太分散？看这里就够了！ 国家战略宏阔，但地方细则散落各地，难以系统把握？ 政策更新频繁，担心遗漏关键机遇或误判监管方向？ 研究竞品布局或规划自身发展时，缺乏权威的政策依据？ 一、内容全面系统 在生物制造浪潮中，您是否也曾面临这些困扰？ 近年，生物制造作为国家战略性新兴产业的重要组成部分，如何精准、系统地把握政策导向，已成为生物制造行业参与者的核心需求之一。 为此， synbio深波 团队收集、梳理汇编形成《中国生物制造产业政策汇编》，旨在打造一部 及时、准确、全面 的政策工具手册，为生物制造及合成 生物学领域从业者提供清晰、便捷的政策脉络参考，助力把握行业发展机遇。 这不是简单的文件列表，而是为您定制的决策支持系统： 覆盖国家至省、市、区（县）各级政策文件，兼顾宏观战略与地方落实措施。汇编收录近百 条精选政策文件，涵盖国家层面及26个省、直辖市、自治区的相关规划、行动方案与配套支 持政策，提供全景式政策脉络。 二、时效性强 精准收 录 截至2025年10月 的政策内 容，贴合行业当下发展的政策参考需求。 三、精准聚焦 精准服务生物制造及合成生物学领域企业决策者、产业研究者、投资分析师、政策制定者等 ...